Integrating molecular medicine into the US health-care system: Opportunities, barriers, and policy challenges
Integrating molecular medicine into the US health-care system: Opportunities, barriers, and policy challenges
复制标题
DOI：
10.1038/sj.clpt.6100319
复制
发表时间：
2007-10-01
影响因子：
6.7
通讯作者：
Carlson, R. J.
中科院分区：
文献类型：
--
作者：
Deverka, P. A.;Doksum, T.;Carlson, R. J.
关于使用分子数据进行风险分层和针对个体量身定制卫生保健干预的概念——一种被广泛定义为分子医学（MM）的策略——的科学支持正在积累。基于分子的卫生保健技术正开始进入临床实践，但它们的使用揭示了有效提供有针对性的卫生保健的许多科学、经济和组织障碍。我们进行了一项定性访谈研究，以描述MM景观，重点是从MM和医疗保健的广泛利益相关者那里引出该领域的政策建议。分子医学得到了广泛的支持，但需要在如何评估基于分子的技术、如何资助和提供卫生保健以及如何培训临床医生和消费者并为其使用做好准备等方面做出改变。特别是，研究人员和开发人员需要积极参与各种临床整合策略，以实现MM的承诺。
Scientific support about the concept of using molecular data for risk stratification and tailoring health-care interventions to the individual -a strategy broadly defined as molecular medicine ( MM) -is accumulating. Molecular-based health-care technologies are beginning to enter clinical practice, but their use has revealed many scientific, economic, and organizational barriers to the effective delivery of targeted health care. We conducted a qualitative interview study to describe the MM landscape, with an emphasis on eliciting policy recommendations for the field from a broad range of stakeholders in MM and health care. Molecular medicine has widespread support but will require changes in how molecular-based technologies are evaluated, how health care is financed and delivered, and how clinicians and consumers are trained and prepared for its use. In particular, researchers and developers need to become active participants in a variety of clinical integration strategies to realize the promise of MM.